-
Recently Validated Methods
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
1 |
4-Methyl amino antipyrine |
antipyrine |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
300 |
90000 |
2 |
Drospirenone |
Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
K3EDTA |
0.20 |
100 |
3 |
Erdosteine |
Thiol derivative |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
15.00 |
3000 |
4 |
Mesalamine |
Anti-inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.0 |
3500 |
5 |
Anti-inflammatory |
Iron Defficiency Anaemia |
Human Serum |
NA |
ICP OES |
Optima 8000 |
400.00 |
50000 |
6 |
Total Iron |
Iron Defficiency Anaemia |
Human Serum |
NA |
ICP OES |
Optima 8000 |
400.00 |
800000 |
-
Premium Methods (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
1 |
4-Plex Amino acid (O-Acetyl-L-Carnitine, L- Carnitine, Creatine and L-Citrulline). |
Amino acids |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
40.0 80.0 |
8000 16000 |
2 |
Aspirin + Salicylic acid (Sensitive) |
Psoriasis |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
2.00 |
500 |
3 |
Amino Acids (20 amino acids) |
Amino Acids |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
100 150 500 1000 2000 |
4000 6000 20000 40000 80000 |
4 |
Amphotericin B (Free) |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
5.00 |
2500 |
5 |
Amphotericin B (Liposomal ) |
Antifungal |
Human Plasma |
Sodium Heparin |
LC/MS/MS |
LCMS-8050 |
100 |
40000 |
6 |
Aspirin |
anti-inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
3000 |
7 |
Aspirin + Salicylic acid (Sensitive) |
Analgesic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
2.00 150 |
1200 10000 |
8 |
Atorvastatin + 2 - Hydroxy Atorvastatin+ 4 - Hydroxy Atorvastatin+ Glimpride+ Glimpride M1 Metabolite |
Antihyperlipidemic Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 0.10 0.05 0.50 0.50 |
40 40 20 200 200 |
9 |
5-Azacitidine |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
10.0 |
2500 |
10 |
Bupropion + Hydroxy Bupropion+ Erythro Bupropion + Threo Bupropion |
Antidepressant and Smoking cessation |
Human Plasma |
Sodium Heparin |
LC/MS/MS |
Premier XE |
3.00 10.0 3.00 5.00 |
900 3000 900 1500 |
11 |
Bupropion + Hydroxy Bupropion + Erythro Bupropion + Threo Bupropion |
Antidepressant |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
1.00 3.00 0.80 2.50 |
300 900 240 750 |
12 |
Bupropion + Hydroxy Bupropion+ Erythrohydro Bupropion + Threohydro Bupropion |
Antidepressant |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
0.60 4.00 0.30 1.20 |
300 2000 150 600 |
13 |
Dabigatran(Total) |
Thrombin Inhibitor |
Human Plasma |
Sodium citrate |
LC/MS/MS |
LCMS-8050 |
1.00 |
400 |
14 |
Disulfiram |
For Chronic Alcoholism |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
25.0 |
5000 |
15 |
Docetaxel(Free) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
600 |
16 |
Doxorubicin Metabolite (Doxorubicinol) |
Oestrogen Progestogen |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.25 |
20 |
17 |
Doxorubicin(Free) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
50.0 |
5000 |
18 |
Doxorubicin(Liposomal) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
250 |
50000 |
19 |
Doxorubicin (Total) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
250 |
50000 |
20 |
Doxorubicin (Free) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
10.0 |
5000 |
-
Premium Methods (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
21 |
Doxorubicin (Liposomal)) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
150 |
60000 |
22 |
Doxorubicin (Free ) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
2000 |
23 |
Doxorubicin (Liposomal) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
150 |
60000 |
24 |
Ergocalciferol |
Vitamin D2 |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.10 |
100 |
25 |
Estrone Unconjugated + Estradiol Unconjugated + Norethindrone |
Oestrogen Oestrogen Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.003 0.001 0.100 |
0.400 0.133 13.3 |
26 |
Estrone (Total) |
Oestrogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
50.0 |
27 |
Ethinyl Estradiol(Sensitive) + Levonorgestrel |
Oestrogen Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.002 0.100 |
0.250 25.0 |
28 |
Equilin Total + ∆8,9-dehydroestrone Total |
Oestrogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.050 0.025 |
8.00 4.00 |
29 |
Estrone Total |
Oestrogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.050 |
15.0 |
30 |
Estrone Uncojugated + Equilin Unconjugated + ∆ 8,9 Dehydroestrone Unconjugated |
Oestrogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.0030 0.0045 0.0045 |
0.400 0.600 0.600 |
31 |
Estrone (Unconjugated) + Estradiol (Unconjugated) |
Oestrogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.003 0.001 |
0.48 0.16 |
32 |
Fesoterodine + 5-OH Methyl Tolterodine |
Urinary Iincontinence |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.01 0.02 |
7.5 15.0 |
33 |
Fingolimod + Fingolimod Phosphate |
Multiple sclerosis |
Human Blood |
K3EDTA |
LC/MS/MS |
API 5500 |
0.04 0.04 |
5.00 5.00 |
34 |
Fingolimod + Fingolimod phosphate |
Multiple sclerosis |
Human Blood |
K3EDTA |
LC/MS/MS |
API 5500 |
0.010 0.010 |
5.00 5.00 |
35 |
Fluphenazine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.003 |
2.10 |
36 |
(+)-3R 5S Fluvastatin + (-)-3S 5R Fluvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.60 0.60 |
300 300 |
37 |
Fluticasone Propionate |
Corticosteroid, Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.002 |
500 |
38 |
Fluticasone Propionate |
Corticosteroid, Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.0008 |
1 |
39 |
Formoterol |
Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.0004 |
0.20 |
40 |
Isosorbide Dinitrate + Isosorbide 2-mono nitrate + Isosorbide 5-mono nitrate |
Angina Pectoris, Congestive Heart Failure |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.40 2.00 2.00 |
100 500 500 |
-
Premium Methods (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
41 |
13-cis-Retinoic Acid+ 4-Keto 13-cis-Retinoic Acid |
Vitamin A |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
5.00 10.0 |
1000 2000 |
42 |
2-Hydroxy Oleic Acid |
Synthetic derivative of Oleic Acid |
Human Plasma |
Na-Heparin |
LC/MS/MS |
API 4000 |
25.0 |
25000 |
43 |
R-Ibuprofen+ S-Ibuprofen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1000 |
32000 |
44 |
R-Ibuprofen + S-Ibuprofen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
200 200 |
70000 70000 |
45 |
Isoniazide + Rifampicin + 25 -Desacetyl Rifampicin+ Ethambutol + Pyrazinamide |
Antitubercular |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
60 15 25 15 200 |
6000 1500 2500 1500 20000 |
46 |
R-Ketoprofen + S-Ketoprofen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
25.0 25.0 |
15000 15000 |
47 |
R-Lercanidipine + S-Lercanidipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.025 0.025 |
20.0 20.0 |
48 |
Lurasidone Metabolite 14283 |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
1000 |
49 |
Metformin+ Pioglitazone+ Hydroxy Pioglitazone |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.00 |
2400 |
50 |
R-Metoprolol+ S-Metoprolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
500 |
51 |
S-Methyl N, N- Diethyl dithiocarbamate (Disulfiram Secondary Metabolite ) |
For Chronic Alcoholism (Disulfiram) |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
5.00 |
1000 |
52 |
RSSS -Nebivolol + SRRR-Nebivolo |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.020 0.020 |
6.00 6.00 |
53 |
N-Acetyl-L-Cysteine |
Chronic bronchopulmonary disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
20.0 |
4000 |
54 |
Niacin + Nicotinuric Acid(Metabolite) |
Vitamin |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 15.0 |
1000 3000 |
55 |
Nitroglycerin + 1, 2-Dinitroglycerin + 1, 3-Dinitroglycerin |
Vasodilator |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.020 0.050 0.050 |
2.00 5.00 5.00 |
56 |
Nitroglycerin + 1,2-Dinitroglycerin + 1,3-Dinitroglycerin |
Vasodilator |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.010 0.020 0.010 |
5.00 10.0 5.00 |
57 |
Paclitaxel (Free, Unbound) |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
1.00 |
1500 |
58 |
Paclitaxel (Free) |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
10.0 |
2000 |
59 |
Penicillamine |
Chelating Agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
15.0 |
4000 |
60 |
Phenindione |
Anticoagulant/Vitamin K antagonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
50.0 |
20000 |
-
Premium Methods (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
61 |
Prednisolone |
Corticosteroid |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
1000 |
62 |
Propranolol (Total) + 4- Hydroxy Propranolol (Total) |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
1.00 0.500 |
500 250 |
63 |
cis & trans-Phytonadione |
Vitamin K |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.100 0.100 |
150 150 |
64 |
R-Praziquantel + S-Praziquantel |
Anthelmintic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 2.00 |
2000 2000 |
65 |
Progesterone |
Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.025 |
25.0 |
66 |
Propranolol Total + 4-OH Propranolol Total |
Beta–adrenoceptor Blocking Agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
2.00 |
500 |
67 |
R-(+) -trans -tranylcypromine + S-(-) -trans-tranylcypromine |
Antidepressant and Anxiolytic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.100 0.200 |
40.0 80.0 |
68 |
Trientine + N1 -Acetyl triethylenetetramine |
Chelating agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
6.00 10.0 |
11500 2500 |
69 |
Trientine + N1 -Acetyl triethylenetetramine + N1,N10 - Diacetyl triethylenetetramine |
Chelating agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
10.0 10.0 3.00 |
2000 2000 600 |
70 |
Rivastigmine(Sensitive) |
Alzheimer's & Parkinson's Disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.05 |
20.0 |
71 |
Tiopronin |
Cystinuria |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
20.0 |
12000 |
72 |
Tiotropium |
Anticholinergic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.20 pg/mL |
100 pg/mL |
73 |
R-Warfarin + S-Warfarin |
Anticoagulant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 1.00 |
1000 1000 |
-
Pharmacodynamic / Pharmacokinetic / Immunogenicity Determination
(Validated Kit / LCMSMS Method)
Sr. No. |
Activity/Marker |
Purpose |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
1 |
Nitrate |
Marker For the Activity of Nitric oxide synthase and the production of Nitric oxide radicals |
Human Plasma |
K3EDTA |
Colourimetric |
Microplate Reader |
5 µM |
35 µM |
2 |
Nitrite |
Marker For the Activity of Nitric
oxide synthase and the
production of Nitric oxide
radicals |
Human Plasma |
K3EDTA |
Colourimetric |
Microplate Reader |
0.0004 |
0.20 |
3 |
Anti X |
LMWH therapy is monitored by the ratio of anti-factor Xa and Anti Factor IIa assay, The amount of residual factor Xa or Factor IIa is inversely proportional to the amount of heparin/LMWH in the plasma |
Human Plasma |
Na-Citrate |
Chromogenic |
Microplate Reader |
0.1 IU/mL |
1 IU/mL |
4 |
Anti IIa |
LMWH therapy is monitored by the ratio of anti-factor Xa and Anti Factor IIa assay, The amount of residual factor Xa or Factor IIa is inversely proportional to the amount of heparin/LMWH in the plasma |
Human Plasma |
Na-Citrate |
Chromogenic |
Microplate Reader |
0.05 IU/mL |
0.2 IU/mL |
5 |
TFPI |
Extrinsic Pathway- Tissue Factor Pathway Inhibitor, For Determination of heparin Presence. |
Human Plasma |
CTAD |
ELISA- Colorimetric |
Microplate Reader |
31.25 pg/mL |
2.0 ng/mL |
6 |
C-Peptide |
NA |
Human Serum |
NA |
ELISA |
Microplate Reader |
28.89 pM |
850 pM |
7 |
C-Peptide (Human) |
NA |
Human Serum |
NA |
ECLIA |
Cobas e411 |
40 pmol/L |
4000 pmol/L |
8 |
G-CSF |
Febrile Neutropenia |
Human Serum |
NA |
ELISA |
Microplate Reade |
2.014 |
50.0 |
9 |
Heparin Clotting Assay |
To determine the clotting time difference in presence of LMWH |
Human Plasma |
CTAD |
Clotting Assay |
Coagulation Analyzer |
0.15 IU/mL |
1.0 IU/mL |
10 |
IgG |
Immunoglobulin- IgG, specific Heparin antibody qualitative detection for immunogenicity of LMWH |
Human Serum |
NA |
Qualitative-ELISA Method |
Microplate Reader |
NA |
NA |
11 |
IgA |
Immunoglobulin- IgA, specific Heparin antibody qualitative detection for immunogenicity of LMWH |
Human Serum |
NA |
Qualitative-ELISA Method |
Microplate Reader |
NA |
NA |
12 |
IgM |
Immunoglobulin- IgM, specific Heparin antibody qualitative detection for immunogenicity of LMWH |
Human Serum |
NA |
Qualitative-ELISA Method |
Microplate Reader |
NA |
NA |
13 |
IgGAM |
Immunoglobulin- IgG, IgM and IgA, specific Heparin antibodies qualitative detection for immunogenicity of LMWH |
Human Serum |
NA |
Qualitative-ELISA Method |
Microplate Reader |
NA |
NA |
14 |
Insulin Human |
Antidiabetic |
Human Serum |
NA |
ECLIA |
Cobas e411 |
10 pmol/L |
2500 pmol/L |
15 |
Insulin Aspart |
Antidiabetic |
Human Serum |
NA |
ELISA |
Microplate Reader SYNERGY H1 |
15.714 pM |
500 pM |
16 |
Insulin Aspart |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.100 |
5.00 |
17 |
A-H-PF4 |
Anti Heparin Platlate factor |
Human Plasma |
CTAD |
ELISA- Colorimetric |
Microplate Reader |
NA |
NA |
18 |
Total Iron |
For Estimation of total Iron after Iron sucrose therepy |
Human Serum |
K3EDTA |
LC/MS/MS |
API 3000 |
2.0 |
1000 |
19 |
Teriperatide (PTH) |
Osteoporosis |
Human Plasma |
K3EDTA |
ELISA |
Microplate Reader |
0.015 |
0.20 |
20 |
Transferrin bound Iron(TBI) |
For Estimation of transferrin bound Iron after Iron sucrose therapy |
Human Serum |
NA |
Colorimetric |
Microplate Reader |
200 ng/mL |
8000 ng/mL |
-
Validated Methods for New Chemical Entities
Sr. No. |
In-House ID |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
1 |
VIN-NCE-001 PL-1 |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.5 |
500 |
2 |
VIN-NCE-001 UR-1 |
Human Urine |
NA |
LC/MS/MS |
API 4000 |
5.0 |
5000 |
3 |
VIN-NCE-002 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
10.0 |
2000 |
4 |
VIN-NCE-003 P |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
20.0 |
5000 |
5 |
VIN-NCE-004 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.50 |
150 |
6 |
VIN-NCE-005 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.50 |
100 |
7 |
VIN-NCE-006 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
1.00 |
1000 |
8 |
VIN-NCE-007 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
5.00 |
5000 |
9 |
VIN-NCE-008 PL |
Human Plasma |
K2 EDTA |
LC/MS/MS |
API 4000 |
0.10 |
100 |
10 |
VIN-NCE-008 UR |
Human Urine |
NA |
LC/MS/MS |
API 4000 |
1.00 |
1000 |
11 |
VIN-NCE-009 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.10 |
100 |
12 |
VIN-NCE-009 UR |
Human Urine |
NA |
LC/MS/MS |
API 4000 |
1.00 |
1000 |
13 |
VIN-NCE-010 PL |
Human Plasma |
K3 EDTA |
LC/MS/MS |
API 3000 |
5.00 |
5000 |
14 |
VIN-NCE-011 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
5.00 |
5000 |
15 |
VIN-NCE-012 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
0.50 |
500 |
16 |
VIN-NCE-014 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
25.0 |
1000 |
17 |
VIN-NCE-013 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.50 |
500 |
18 |
VIN-NCE-012 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
1.00 |
500 |
19 |
VIN-NCE-016 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.10 |
100 |
20 |
VIN-NCE-017 BL |
Human Blood |
Na Heparin |
LC/MS/MS |
Premier XE |
0.50 |
100 |
-
Validated Methods for New Chemical Entities
Sr. No. |
In-House ID |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
21 |
VIN-NCE-018 BL |
Human Blood |
Na Heparin |
LC/MS/MS |
API 3000 |
3.0 |
1200 |
22 |
VIN-NCE-019 PL |
Human Urine |
EDTA |
LC/MS/MS |
API 2000 |
10.0 |
250 |
23 |
VIN-NCE-020 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 2000 |
1.00 |
25.0 |
24 |
VIN-NCE-021 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.030 |
100 |
25 |
VIN-NCE-022 SK |
Human Skin |
Na Heparin |
LC/MS/MS |
API 3000 |
12.0 |
9000 |
26 |
VIN-NCE-023 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
3.00 |
2400 |
27 |
VIN-NCE-024 PL |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.50 |
1000 |
28 |
VIN-NCE-025 UR |
Human Urine |
Na Heparin |
LC/MS/MS |
Premier XE |
0.50 |
1000 |
29 |
VIN-NCE-026 PL |
Human Blood |
EDTA |
LC/MS/MS |
API 3000 |
0.30 |
200 |
30 |
VIN-NCE-027 PL |
Human Urine |
EDTA |
LC/MS/MS |
API 4000 |
2.00 |
1000 |
31 |
VIN-NCE-028 PL |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
5.00 |
3000 |
32 |
VIN-NCE-029 PL |
Human Urine |
Na Heparin |
LC/MS/MS |
Premier XE |
2.00 |
2500 |
33 |
VIN-NCE-030 TI |
Colon tissue |
NA |
LC/MS/MS |
API 3000 |
12.0 |
9000 |
34 |
VIN-NCE-022 CT |
Colon tissue |
NA |
LC/MS/MS |
API 3000 |
12.0 |
9000 |
35 |
VIN-NCE-012 PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 4000 |
0.500 |
5000 |
36 |
VIN-NCE-032 PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 5500 |
0.050 |
50.0 |
37 |
VIN-NCE-034 PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 4000 |
0.005 |
5.50 |
38 |
VIN-NCE-038 UR |
Human Urine |
NA |
LC/MS/MS |
API 3200 |
1.00 |
1000 |
39 |
VIN-NCE-037 UR |
Human Urine |
NA |
LC/MS/MS |
API 3200 |
0.10 |
10000 |
40 |
VIN-NCE-035 PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 3200 |
5.0 |
5000 |
-
Validated Methods for New Chemical Entities
Sr. No. |
In-House ID |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
41 |
VIN-NCE-041 PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 |
2000 |
42 |
VIN-NCE-039PL |
Human Urine |
K2EDTA |
LC/MS/MS |
LCMS-8060 |
1.00 |
1000 |
43 |
VIN-NCE-043 PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 4000 |
2.0 |
1000 |
44 |
VIN-NCE-037UR |
Human Urine |
NA |
LC/MS/MS |
API 3200 |
10.00 |
10000 |
45 |
VIN-NCE-042PL |
Human Plasma |
K2EDTA |
LC/MS/MS |
LCMS-8050 |
0.02 |
10 |
46 |
VIN-NCE-044PL (Drug + Metabolite) |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
1.00 1.00 |
1000 1000 |
47 |
VIN-NCE-040PL |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 |
1000 |
48 |
VIN-NCE-045PL |
Human Urine |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
2000 |
49 |
VIN-NCE-046PL (Drug + Metabolite) |
Human Blood |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 1.00 |
5000 1000 |
50 |
VIN-NCE-047UR |
Human Urine |
NA |
LC/MS/MS |
API 4000 |
1.00 |
2000 |
51 |
VIN-NCE-048PL |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
1.0 |
5000 |
52 |
VIN-NCE-049PL (Drug + Metabolite) |
NCE |
Human Plasma |
K3EDTA |
LC/MS/MS |
0.005 0.20 |
5.00 20.0 |
53 |
VIN-NCE-050PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
1.0 |
5000 |
54 |
VIN-NCE-51PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
0.50 0.50 |
1000 1000 |
55 |
VIN-NCE-52PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
0.0 |
50 |
56 |
VIN-NCE-53UR |
NCE |
Human Urine |
NA |
LC/MS/MS |
10.0 |
50 |
57 |
VIN-NCE-54PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
50.0 |
20000 |
58 |
VIN-NCE-55PL |
NCE |
Human Plasma |
K3EDTA |
HPLC-UV |
300µg/mL |
5000µg/mL |
59 |
VIN-NCE-56PL |
NCE |
Human Plasma |
K3EDTA |
LC/MS/MS |
0.0 |
20 |
60 |
VIN-NCE-57PL |
NCE |
Human Plasma |
K3EDTA |
LC/MS/MS |
1.0 |
1000 |
-
Validated Methods for New Chemical Entities
Sr. No. |
In-House ID |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ (ng/mL) |
ULOQ (ng/mL) |
61 |
VIN-NCE-58PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
1.00 |
10000 |
62 |
VIN-NCE-59PL |
NCE |
Human Plasma |
K3EDTA |
LC/MS/MS |
2.0 |
1000 |
63 |
VIN-NCE-60PL |
NCE |
Na Heparin |
Na Heparin |
LC/MS/MS |
2.0 |
2500 |
64 |
VIN-NCE-61PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
0.5 |
1500 |
65 |
VIN-NCE-62UR |
NCE |
Human Urine |
NA |
LC/MS/MS |
2.0 |
4000 |
66 |
VIN-NCE-63PL |
NCE |
Human Plasma |
K2EDTA |
LC/MS/MS |
0.0 |
20 |
-
Methods Under Development / Validation
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
1 |
20 Amino Acid (UR) |
Amino acids |
Human Urine |
NA |
LC/MS/MS |
LCMS-8040 |
38.0 |
60000.0 |
2 |
Amlodipine + Valsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.025 20.0 |
15.0 12000 |
3 |
Buspirone |
Anxiolytic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
500 |
4 |
Carbamazepine |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
20.00 |
10000 |
5 |
Cariprazine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 |
50.0 |
6 |
Clozapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.40 |
100 |
7 |
Diazepam |
benzodiazepines |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
800 |
8 |
Diclofenac |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
40.0 |
9 |
Dimenhydrinate |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
200 |
10 |
Fluvoxamine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.40 |
400 |
11 |
Fluticasone Propionate (In presence of Salmeterol) |
Corticosteroid, Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.002 |
500 |
12 |
Ibuprofen + Paracetamol |
anti-inflammatory & antipyretics |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
100.00 30.00 |
30000.0 9000.0 |
13 |
Insulin Glargine + Metabolite M1 + Metabolite M2 |
Antidiabetic |
Human Plasma |
K2EDTA |
LC/MS/MS |
LCMS-8060 |
0.10 0.10 0.10 |
5.00 5.00 5.00 |
14 |
Lapatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
10.0 |
8000 |
15 |
Mirabegron |
Urinary incontinence |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 5500 |
0.10 |
80.0 |
16 |
Midostaurin |
Antineoplastic agents |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
5.00 |
2500.0 |
17 |
N-Acetyl -L-Cysteine (UR) |
Amino acids |
Human Urine |
NA |
LC/MS/MS |
LCMS-8040 |
20.00 |
4000.0 |
18 |
Norethisterone (Norethindrone) |
Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
20.0 |
19 |
Perindropril + Perindoprilat |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 0.20 |
300 60.0 |
20 |
Pazopanib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
300 |
150000 |
-
Methods Under Development / Validation
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
21 |
Progesterone |
Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.10 |
100 |
22 |
Propranolol & 4- Hydroxy Propranolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
1.00 0.50 |
500 250 |
23 |
Saxagliptin + 5-Hydroxy Saxagliptin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 0.40 |
100 200 |
24 |
Tiotropium |
bronchodilators |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.0001 |
0.050 |
25 |
Transferrien Bound Iron (TBI) |
Iron Defficiency Anaemia |
Human serum |
NA |
ICP OES |
Optima 8000 |
400 |
50000 |
26 |
Total Iron (TOI) |
Iron Defficiency Anaemia |
Human serum |
NA |
ICP OES |
Optima 8000 |
400 |
800000 |
27 |
Verapamil + Norverapamil |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.50 0.50 |
250 250 |
28 |
Vigabatrin |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
500 |
300000 |
29 |
Zileuton |
Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
20.0 |
10000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
1 |
Abacavir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
30.0 |
7500 |
2 |
Abacavir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
30.000 |
9000.0 |
3 |
Abacavir + Lamivudine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
24.0 60.0 |
6000 15000 |
4 |
Abiraterone |
Metastatic prostate cancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.500 |
200.0 |
5 |
Abiraterone |
Metastatic prostate cancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
5.00 |
2000 |
6 |
Abiraterone |
Metastatic prostate cancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.400 |
500.0 |
7 |
Acetaminophen (Paracetamol) |
Antipyretic, Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
300.00 |
20000 |
8 |
Acetaminophen (Paracetamol) |
Antipyretic, Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
200.000 |
20000.0 |
9 |
Acetazolamide |
Carbonic anhydrase inhibitor, diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
20.0 |
20000 |
10 |
Acetazolamide |
Carbonic anhydrase inhibitor, diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.000 |
5000.0 |
11 |
Acetazolamide |
Carbonic anhydrase inhibitor, diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
30.00 |
18000 |
12 |
Acetazolamide |
Carbonic anhydrase inhibitor, diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS - 8050 |
60.000 |
30000.0 |
13 |
Acitretin |
Psoriasis |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
0.20 |
300 |
14 |
Acitretin+ 13 - Cis Acitretin |
Psoriasis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
500 |
15 |
Acyclovir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
2500 |
16 |
Afatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
200 |
17 |
Agomelatine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.005 |
10.0 |
18 |
Agomelatine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.005 |
50.0 |
19 |
Alfuzosin |
Benign prostatic hyperplasia |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.050 |
30.0 |
20 |
Alfuzosin |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.40 |
80 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
21 |
Alimemazine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.020 |
10.0 |
22 |
Aliskiren |
Renin inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.30 |
300 |
23 |
Alogliptin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.80 |
400 |
24 |
Alosetron |
5-HT3 Antagonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.05 |
20 |
25 |
Alprazolam |
Anxiolytic |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.20 |
40 |
26 |
Allopurinol |
Anti gout |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
15.0 |
9000 |
27 |
Alverine + 4-Hydroxy Alverine |
Smooth muscle relaxant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.01 0.05 |
3.00 15.0 |
28 |
Aminocaproic acid |
Bleeding Disorders |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
500 |
100000 |
29 |
Amisulpride |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
2500 |
30 |
Amlodipine + Valsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 100 |
10.0 10000 |
31 |
Amlodipine + Valsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 40.0 |
12.0 4800 |
32 |
Albendazole + Albendazole Sulfoxide |
Anthelmintic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 4.00 |
100 2000 |
33 |
Amantadine |
Antiviral and an Antiparkinsonian drug |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
2.00 |
1000 |
34 |
Ambroxol + Gauifenesin |
Expectorant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.40 5.00 |
200 2500 |
35 |
Amiodarone |
Antiarrhythmic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
1000 |
36 |
Amitriptyline+ Nortriptyline |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 0.08 |
120 48.0 |
37 |
Amitriptyline+ Nortriptyline |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 0.09 |
120 48.1 |
38 |
Amitriptyline+ Nortriptyline |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 0.050 |
80.0 20.0 |
39 |
Amlodipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.03 |
10.0 |
40 |
Amlodipine + Celecoxib |
Antihypertensive / NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 10.0 |
25.0 2500 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
41 |
Amlodipine + HCTZ + Olmesartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.05 1.00 10.0 |
15.0 300 3000 |
42 |
Amlodipine + Olmesartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.040 10.0 |
12.0 3000 |
43 |
Amlodipine + Telmisartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.05 5.00 |
10.0 1000 |
44 |
Amlodipine + Valsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 40.0 |
12.0 4800 |
45 |
S-Amlodipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.03 |
2.0 |
46 |
S-Amlodipine+ Hydrochlorothiazide |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API4000 |
0.03 1.00 |
12.0 400 |
47 |
S-Amlodipine + Hydrochlorothiazide |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API4000 |
0.03 1.00 |
12.0 400 |
48 |
Amoxicillin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
160 |
30000 |
49 |
Amoxicillin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
200 |
30000 |
50 |
Amoxicillin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
50.0 |
25000 |
51 |
Anastrozole |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.20 |
60 |
52 |
Apixaban |
Oral Anticoagulant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
1.00 |
400 |
53 |
Apremilast |
Psoriatic Arthritis |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
4.00 |
800 |
54 |
Aprepitant |
Antiemetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
20.0 |
4000 |
55 |
Aprepitant |
Antiemetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
20.0 |
8000 |
56 |
Aripriprazole |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.50 |
400 |
57 |
Aripiprazole |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.50 |
200 |
58 |
Aripiprazole |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
800 |
59 |
Aripriprazole + Escitalopram |
Antipsychotic, Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.25 0.10 |
65.0 24.0 |
60 |
Armodafinil |
Wakefulness promoting agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
50 |
15000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
61 |
Artemether+ Dihydroartimisnin |
Antimalarial |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
3.00 |
360 |
62 |
Artimether + Dihydroartemisinin |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 0.50 |
300 300 |
63 |
Artesunate + Dihydroartemisinin |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.800 0.800 |
500 500 |
64 |
Asenapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.10 |
20.0 |
65 |
Asenapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
20.0 |
66 |
Aspirin + Salicylic Acid |
Analgesic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 2000 |
2000.00 |
80000 |
67 |
Aspirin + Salicylic acid |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
4.0 100 |
2000 7000 |
68 |
Aspirin(Sensitive) |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
10.00 |
2000 |
69 |
Atazanavir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
30.0 |
15000 |
70 |
Atazanavir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS - 8050 |
20.0 |
8000 |
71 |
Atenolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
8.00 |
2200 |
72 |
Atenolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
10.0 |
1500 |
73 |
Atomoxetine |
Hyperactivity disorder (ADHD) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
2000 |
74 |
Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.20 |
200 |
75 |
Atorvastatin |
Antihyperlipidemic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.50 |
300 |
76 |
Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.25 |
400 |
77 |
Atorvastatin + 2 - Hydroxy Atorvastatin+ 4 - Hydroxy Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.25 0.50 0.50 |
50 100 100 |
78 |
Atorvastatin + 2 - Hydroxy Atorvastatin+ 4 - Hydroxy Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 0.10 0.05 |
100 100 50 |
79 |
Atorvastatin+ 2 - Hydroxy Atorvastatin+ 4 - Hydroxy Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.2 0.2 0.1 |
200 200 100 |
80 |
Atorvastatin + 2- Hydroxy Atorvastatin + 4- Hydroxy Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.020 0.020 0.010 |
20.0 20.0 10.0 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
81 |
Atorvastatin + 2 - Hydroxy Atorvastatin+ 4 - Hydroxy Atorvastatin+ Glimpride |
Antihyperlipidemic Antidiabetic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.1 0.1 0.05 0.50 |
40 40 20 200 |
82 |
Atorvastatin + 2 - Hydroxy Atorvastatin+ 4 - Hydroxy Atorvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.32 0.224 0.048 |
200 140 30.0 |
83 |
Atovaquone |
Antiprotozoal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
100.00 |
20000 |
84 |
Axitinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.200 |
100 |
85 |
Axitinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.075 |
100 |
86 |
Axitinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Waters QPXE |
0.250 |
150 |
87 |
Azilsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
30.000 |
15000.0 |
88 |
Azilsartan + Chlorthalidone |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
10.0 2.00 |
5000 1000 |
89 |
Azithromycin |
Antibiotics |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
5.00 |
1000 |
90 |
Azithromycin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API3000 |
5.00 |
2000 |
91 |
Azythromycin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.00 |
400 |
92 |
Azithromycin |
Antibiotics |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.00 |
700 |
93 |
Baclofen |
Muscle relaxant and antispastic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
1000 |
94 |
Baclofen |
Muscle relaxant and antispastic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
3.00 |
2400 |
95 |
Barnidipine |
Antihypertensive |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 3000 |
0.02 |
10 |
96 |
Barnidipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS - 8050 |
0.004 |
8.00 |
97 |
Benazepril + Benazeprilat |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
1.00 2.00 |
400 800 |
98 |
Bendroflumethiazide |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
200 |
99 |
Benzonatate + 4-Butylamino Benzoic Acid |
Symptomatic relief of cough |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS - 8050 |
0.050 3.00 |
100 6000 |
100 |
Bexarotene |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
200 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
101 |
Bilastine |
Antihistamine |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
2.00 |
600 |
102 |
Binimetinib |
anti-cancer |
Human Plasma |
Li-Heparine |
LC/MS/MS |
LCMS-8050 |
1.00 |
500 |
103 |
Bisoprolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
0.50 |
100 |
104 |
Bisoprolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 |
150 |
105 |
Bisoprolol + Hydrochlorothiazide |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.50 0.50 |
100 100 |
106 |
Bortezomib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
2.00 |
1400 |
107 |
Bortezomib |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8040 |
0.225 |
50.0 |
108 |
Bortezomib |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8040 |
0.225 |
50.0 |
109 |
Bosentan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
50.00 |
5000 |
110 |
Bosentan(Sensitive ) |
Endothelin receptor antagonis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
20.00 |
5000 |
111 |
Bosentan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
5000 |
112 |
Bosutinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
120 |
113 |
Brexpiprazole |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.20 |
60.0 |
114 |
Brexpiprazole |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.20 |
150 |
115 |
Budesonide |
Glucocorticoid |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
LCMS-8050 |
0.010 |
4.50 |
116 |
Budesonide |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.015 |
4.50 |
117 |
Budesonide |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.010 |
8.00 |
118 |
Bumetanide |
Diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
1.00 |
200 |
119 |
Bupivacaine |
Local Anesthetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premiere XE |
5.00 |
2500 |
120 |
Bupivacaine |
Local Anesthetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
500 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
121 |
Bupropion + Hydroxy Bupropion |
Antidepressant |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3000 |
1.50 |
300 |
122 |
Buspiron |
Anxiolytic |
Human Plasma |
Li-Heparine |
LC/MS/MS |
API 3000 |
0.05 |
5.00 |
123 |
Butylscopolamine (Butylhyoscine) |
Abdominal pain |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.002 |
0.25 |
124 |
Butylscopolamine (Butylhyoscine) |
Abdominal pain |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.002 |
800 |
125 |
Cabergoline |
Dopamine receptor agonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.0015 |
0.100 |
126 |
Cabergoline |
Dopamine receptor agonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.0015 |
0.100 |
127 |
Cabozanitinib |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
2.00 |
1000 |
128 |
Canagliflozin |
Antidiabetic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
10.0 |
6000 |
129 |
Canagliflozin + Metformin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 5.00 |
3000 3000 |
130 |
Candesartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
1.00 |
500 |
131 |
Candesartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
700 |
132 |
Candesartan + Hydrochlorothiazide |
Antihypertensive Diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.0 1.0 |
1000 500 |
133 |
Capecitabine |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.00 |
10000 |
134 |
Captopril |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
5.00 |
1000 |
135 |
Carbamazepine |
Antiepileptic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
20.00 |
5000 |
136 |
Carbamazepine |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
20.00 |
10000 |
137 |
Carbamazepine |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
10.0 |
3000 |
138 |
Carbidopa+ Levodopa |
Parkinson's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
2.00 20.0 |
400 4000 |
139 |
Carbidopa + Levodopa |
Parkinson's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.25 20.0 |
150 4000 |
140 |
Carvedilo + 4-Hydroxyphenyl Carvedilol |
Beta–blocker |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.5 0.150 |
100 30.0 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
141 |
Carglumic Acid |
Carbamoyl Phosphate Synthetase 1 activator |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
50.0 |
10000 |
142 |
Cefaclor |
Antibacterial |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
HPLC-UV |
500 |
50000 |
143 |
Cefaclor |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
200 |
20000 |
144 |
Cefadroxil |
Antibiotic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
300 |
60000 |
145 |
Cefadroxil |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
200 |
40000 |
146 |
Cefditoren |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
25.0 |
5000 |
147 |
Cefixime |
Antibacterial |
Human Plasma |
EDTA |
HPLC-UV |
HPLC-UV |
100 |
20000 |
148 |
Cefixime |
Cephalosporin Antibiotic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
25.00 |
15000 |
149 |
Cefixime |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
100 |
20000 |
150 |
Cefpodoxime acid |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
20.0 |
3000 |
151 |
Cefpodoxime acid |
Antibacterial |
Human Plasma |
K3EDTA |
HPLC-UV |
HPLC-UV |
200 |
10000 |
152 |
Cefuroxime acid |
Antibacterial |
Human Plasma |
EDTA |
HPLC-UV |
HPLC-UV |
150 |
30000 |
153 |
Cefuroxime acid |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
75.0 |
1500 |
154 |
Cefuroxime |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
60.0 |
12000 |
155 |
Celecoxib |
NSAID |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
20.00 |
5000 |
156 |
Celecoxib |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
2500 |
157 |
Cephalexin |
Antibacterial |
Human Plasma |
EDTA |
HPLC |
HPLC-UV |
200 |
120000 |
158 |
Cephalexin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
500 |
50000 |
159 |
Cephalexin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
50.0 |
25000 |
160 |
Cetirizine |
Non-sedative Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
5.00 |
1000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
161 |
Chlorpheniramine + Phenylephrine |
Antihistamine Decongestant |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.10 0.05 |
20.0 10.0 |
162 |
Chlorpromazine + 7-Hydroxy Chlorpromazine |
Antipsychotic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.50 0.20 |
250 100 |
163 |
Chlorpromazine + 7-Hydroxy Chlorpromazine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.020 0.020 |
20.0 20.0 |
164 |
Chlorthalidone |
Diruretic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
LC 8040 |
20.0 |
8000 |
165 |
Chlorthalidone |
Diruretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
2.00 |
1000 |
166 |
Chlorthalidone + Telmisartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 2.00 |
250 500 |
167 |
Chlorzoxazone |
Muscle relaxant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
50.0 |
20000 |
168 |
Chlorzoxazone |
Muscle relaxant |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 3200 |
200 |
80000 |
169 |
Cinnargine |
Antihistamine |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
5.00 |
750 |
170 |
Ciprofloxacin |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
100 |
10000 |
171 |
Clarithromycin |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
50.0 |
10000 |
172 |
Clarithromycin + 14(R)-hydroxy-Clarithromycin |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
40.0 15.0 |
8000 3000 |
173 |
Clarithromycin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
5000 |
174 |
Clindamycin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
10.0 |
8000 |
175 |
Clobazam + N-Desmethyl Clobazam |
Antiepileptic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
Premier XE |
5.00 1.00 |
1500 300 |
176 |
Clomipramine + Desmethyl Clomipramine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.00 1.00 |
300 300 |
177 |
Clomipramine + Desmethyl Clomipramine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 0.80 |
50.0 200 |
178 |
Clomipramine + Desmethylclomipramine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 0.050 |
6.0 30.0 |
179 |
Clonazepam |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 |
30.0 |
180 |
Clonazepam |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
20.0 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
181 |
Clonidine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.025 |
2.50 |
182 |
Clonidine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.003 |
1.50 |
183 |
Clopidogre |
Anti–platelet |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
0.20 |
25.0 |
184 |
Clopidogrel |
Anti–platelet |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.050 |
10.0 |
185 |
Clopidogrel |
Anti–platelet |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.005 |
5.00 |
186 |
Clopidogrel |
Anti–platelet |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.010 |
10.0 |
187 |
Clopidogrel+ Clopidogrel Carboxylic acid |
Anti–platelet |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.05 50.0 |
10.0 10000 |
188 |
Clopidogrel Carboxylic acid |
NA |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
50.0 |
10000 |
189 |
Clozapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
1000 |
190 |
Cyclobenzaprine |
Muscle spasm |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.050 |
20.0 |
191 |
Cyclosporin (Ciclosporin) |
Immunosuppressant |
Human Blood |
K3EDTA |
LC/MS/MS |
Premier XE |
5.00 |
2000 |
192 |
Dabigatran (free) |
Thrombin Inhibitor |
Human Plasma |
Na-Citrate |
LC/MS/MS |
API 4000 |
1.00 |
300 |
193 |
Dalfampridine |
Multiple sclerosis |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.40 |
100 |
194 |
Dapagliflozine |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 |
500 |
195 |
Dapsone |
Antileprotic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
25.0 |
5000 |
196 |
Dapsone + N-Acetyl Dapsone |
Antileprotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.045 0.015 |
18.0 6.00 |
197 |
S-Dapoxetine |
Selective serotonin reuptake inhibitor |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
1.00 |
1000 |
198 |
Dapoxetine + Tadalafil |
Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
2.00 2.00 |
800 800 |
199 |
Darifenacin |
Urinary incontinence |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.025 |
5.00 |
200 |
Darifenacin |
Urinary incontinence |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.025 |
12.0 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
201 |
Darunavir |
Antiretroviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
50.0 |
20000 |
202 |
Darunavir |
Antiretroviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premiere XE |
50.0 |
20000 |
203 |
Dasatinib |
Anticancer |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
1.00 |
400 |
204 |
Dasatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
400 |
205 |
Deferasirox |
Iron Chelator |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
100 |
60000 |
206 |
Deferasirox |
Iron Chelator |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
100 |
60000 |
207 |
Deferiprone + Deferiprone Glucuronide |
Iron Chelator |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 2000 |
250 125 |
40000 20000 |
208 |
Desipramine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API4000 |
0.50 |
150 |
209 |
Desipramine + 2-Hydroxy Desipramine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.5 0.15 |
150 45 |
210 |
Desloratadine |
Antihistamine |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.20 |
10.0 |
211 |
Desloratadine + 3-Hydroxy Desloratidine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.05 |
10.0 |
212 |
Desloratidine + 3-Hydroxy Desloratidine |
Antihistamine |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.05 |
10.0 |
213 |
Desloratidine + 3-Hydroxy desloratidine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.025 0.025 |
7.50 7.50 |
214 |
Desmopressin |
Synthetic replacement of vasopressin harmone |
Human Plasma |
K3EDTA |
LC/MS/MS |
APi 5500 |
0.002 |
0.250 |
215 |
Desvenlafaxine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
2.00 |
700 |
216 |
Dexamethasone |
Corticosteroid |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
2.00 |
600 |
217 |
Dexamethasone |
Corticosteroid |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.25 |
100 |
218 |
Dexamethasone |
Corticosteroid |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
150 |
219 |
Dexlansoprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 |
2500 |
220 |
Dextromethorphan + Dextrorphan |
Cough Suppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.10 10.0 |
20.0 2000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
221 |
Dextromethorphan+ Dextrorphan |
Cough Suppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.030 0.030 |
15.0 5.0 |
222 |
Dextromethorphan + Guanafenesin |
Cough Suppressant Expectorant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.10 25.0 |
20.0 5000 |
223 |
Diacerein + Rhein |
Osteoarthritis |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
LCMS-8050 |
15.0 15.0 |
6000 6000 |
224 |
Diazoxide |
Hyperinsulinism |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
30.0 |
12000 |
225 |
Diclofenac |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
25.0 |
4000 |
226 |
Diclofenac |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
10.0 |
4000 |
227 |
Diclofenac |
Analgesic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 2000 |
50.0 |
15000 |
228 |
Dilclofenac |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
4000 |
229 |
Diclofenac |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
40.0 |
40000 |
230 |
Diclofenac + Esomeprazole |
Analgesic Proton pump inhibitor |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
8.00 4.00 |
4000 2000 |
231 |
Dicloxacillin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
200 |
80000 |
232 |
Dicyclomine (Dicycloverine) |
Antispasmodic |
Human Plasma |
EDTA |
LC/MS/MS |
LCMS-8040 |
0.50 |
120 |
233 |
Dihydroartemisinin |
Anitmalerial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
1000 |
234 |
Dihydrotetrabenazine |
Huntington's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 |
200 |
235 |
Diltiazem + N-Desmethyl Diltiazem + Desacetyl Diltiazem |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.5 0.5 0.5 |
450 150 150 |
236 |
Diltiazem + N-Desmethyl diltiazem + Desacetyl diltazem |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
4.00 1.00 0.50 |
1200 300 150 |
237 |
Diphendydramine + Naproxen |
Antihistamine NSAID |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.50 500 |
150 150000 |
238 |
Dipyridamole |
Vasodilator |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 |
4500 |
239 |
Dipyridamole |
Vasodilator |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 |
5000 |
240 |
Disulfiram Metabolite 2 |
For Chronic Alcoholism (Disulfiram) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
250 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
241 |
Disulfiram Primary Metabolite |
NA (Inactive Metabolite of Disulfiram) |
Human Plasma |
K3EDTA |
HPLC-UV |
Shimadzu LC20 |
2.00 |
200 |
242 |
Docetaxel(Total) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
6000 |
243 |
Dofetilide |
Antiarrhythmic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.010 |
5.00 |
244 |
Dolutegravir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
20.0 |
8000 |
245 |
Doltegravir + Emtricitabine+ Tenofovir Alafenamide |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
30.0 20.0 2.00 |
7500 5000 500 |
246 |
Donepezil |
Alzheimer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
200 |
247 |
Donepezil |
Alzheimer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 |
50.0 |
248 |
Donepezil + Memantine |
Alzheimer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 0.50 |
200 200 |
249 |
Donepezil + Memantine |
Alzheimer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 0.30 |
60.0 90.0 |
250 |
Dosulepin |
Antidepressant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 |
120 |
251 |
Doxazosin |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 |
50.0 |
252 |
Doxepin + Nordoxepin |
Antidepressant |
Human Plasma |
EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 0.050 |
80.0 20.0 |
253 |
Doxepin + Nordoxepin |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.005 0.005 |
10.0 10.0 |
254 |
Doxepin + Nordoxepin |
Alzheimer |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 0.050 |
160 40.0 |
255 |
Doxorubicin (Total) |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
150 |
60000 |
256 |
Doxycycline |
Antibacterial |
Human Plasma |
Na HeparinA |
LC/MS/MS |
Premier XE |
10.0 |
5000 |
257 |
Doxycycline |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
10.0 |
1500 |
258 |
Doxycycline |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API3000 |
10.0 |
7000 |
259 |
Doxycycline |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
10.0 |
7000 |
260 |
Dronedarone+ Desbutyl Dronedarone |
Antiarrhythmic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 0.50 |
300 300 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
261 |
Droxidopa |
Parkinson's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
6000 |
262 |
Droxidopa |
Parkinson's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
6000 |
263 |
Duloxetine |
Antidepressant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
0.40 |
150 |
264 |
Duloxetine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
0.50 |
100 |
265 |
Dutastaride |
5-alpha-reductase inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API-4000 |
0.10 |
25.0 |
266 |
Dutasteride |
Benign prostatic hyperplasia |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.010 |
10.0 |
267 |
Dutasteride + Tamsulosin |
BPH (Benign prostatic hyperplasia) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.020 0.10 |
10.0 50.0 |
268 |
Efavirenz |
Antiviral |
Human Plasma |
EDTA |
HPLC |
HPLC-UV |
50.0 |
9000 |
269 |
Efavirenz |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
30.0 |
6000 |
270 |
Eletriptan |
Anti-Migraine |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
0.50 |
250 |
271 |
Eliglustat |
Gaucher's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 |
100 |
272 |
Eltrombopag |
Thrombocytopenia |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
50.0 |
30000 |
273 |
Empagliflozin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
3.00 |
1200 |
274 |
Emtricitabin |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
30.0 |
3000 |
275 |
Emtricitabine + Tenofovir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
20.0 4.00 |
4000 800 |
276 |
Emtricitabine + Tenofovir Alafenamide |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
20.0 2.00 |
5000 500 |
277 |
Enalapril + Enalaprilat |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
5.00 2.00 |
1000 450 |
278 |
Enalapril + Enalaprilate |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 0.50 |
500 250 |
279 |
Enalapril + Enalaprilate |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 0.50 |
500 250 |
280 |
Entacapone + Metabolite |
Parkinson's disease |
Human Plasma |
K3EDTA |
HPLC |
HPLC-UV |
50.0 |
6000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
281 |
Entacapone + Metabolite |
Parkinson's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
25.0 |
6000 |
282 |
E-Entacapone |
Parkinson's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
5000 |
283 |
Entecavir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.040 |
20.0 |
284 |
Enzalutamide |
Metastatic castration-resistant prostate cancer (CRPC) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
10000 |
285 |
Enzalutamide |
Metastatic castration-resistant prostate cancer (CRPC) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
20.0 |
10000 |
286 |
Eplerenone |
Chronic Heart Failure |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
10.0 |
4000 |
287 |
Eprosartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
30.0 |
4000 |
288 |
Eprosartan + Hydrochlorothiazide |
Antihypertensive Diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
30.0 1.00 |
7500 500 |
289 |
Eprosartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
30.0 |
6000 |
290 |
Erlotinib |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
12.5 |
2500 |
291 |
Erlotinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
2500 |
292 |
Erythromycin |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
20.0 |
2000 |
293 |
Erythromycin |
Antimicrobial |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE / API4000 |
10.0 |
4000 |
294 |
Escitalopram |
Antidepressant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.30/td>
| 200 |
295 |
Escitalopram |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
50.0 |
296 |
Escitalopram + S (+) Desmethylcitalopram |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 0.040 |
50.0 10.0 |
297 |
Eslicarbazepine |
Antiepileptic |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
100 |
30000 |
298 |
Esomeprazole |
Proton pump inhibitor |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
10.0 |
3500 |
299 |
Esomeprazole (Sensitive) |
Proton pump inhibitor |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
5.00 |
3500 |
300 |
Esomeprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
4000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
301 |
Esomeprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
800 |
302 |
Esomeprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
2.00 |
800 |
303 |
Esomeprazole + Naproxen |
Proton pump inhibitor NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.0 500 |
1500 150000 |
304 |
Esomeprazole+ Naproxen |
Proton pump inhibitor NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.0 500 |
600 150000 |
305 |
Ethinyl Esterdiol + Levonorgetral |
Oestrogen |
Human Plasma |
Sodium Heparin |
LC/MS/MS |
API 5500 |
0.004 0.10 |
0.50 20.0 |
306 |
Ethosuximide |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
50.0 |
20000 |
307 |
Ethosuximide |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
800 |
200000 |
308 |
Etodolac |
Non-steroidal Anti- inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
500 |
80000 |
309 |
Etodolac |
Nonsteroidal anti-inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
250 |
80000 |
310 |
Etoposide |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
20.0 |
8000 |
311 |
Etoricoxib |
COX-2 selective inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API2000 |
10.0 |
5000 |
312 |
Etravirine |
Antiviral |
Human Plasma |
EDTA |
LC/MS/MS |
LCMS-8050 |
2.00 |
1200 |
313 |
Everolimus |
Anticancer |
Human Blood |
K3EDTA |
LC/MS/MS |
API3000 |
0.30 |
200 |
314 |
Exemestane |
Aromatase inhibitor, Anticancer |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.10 |
40.0 |
315 |
Ezetimib + Ezetimibe-O-beta-glucuronide |
Antihyperlipidemic |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
0.10 1.00 |
25.0 250 |
316 |
Ezetimibe + Ezetimibe Phenoxy Glucuronide |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.10 1.00 |
30.0 300 |
317 |
Ezetimibe(Unconjugated) |
Antihyperlipidemic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.13 |
20.0 |
318 |
Ezetimib (Total) |
Antihyperlipidemic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
LCMS-8040 |
1.000 |
200.0 |
319 |
Ezetimibe+ Ezetimibe Phenoxygluconoride |
Antihyperlipidemic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.10 1.00 |
15.0 150 |
320 |
Famotidine |
Antihistamine (H2 Antagonist) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
300 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
321 |
Febuxostat |
Inhibitor of Xanthine Oxidase |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
50 |
10000 |
322 |
Felodipine |
Antihypertensive |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.20 |
10.0 |
323 |
Felodipine |
Calcium channel blocker |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
10.0 |
324 |
Felodipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.015 |
15.0 |
325 |
Fenofibric Acid |
Antihyperlipidemic |
Human Plasma |
Sodium Heparin |
LC/MS/MS |
API 2000 |
25.0 |
10000 |
326 |
Fenofibric Acid |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
50.0 |
20000 |
327 |
Fenofibric Acid |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
50.0 |
20000 |
328 |
Fenoprofen |
Non-steroidal Anti- inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
250 |
100000 |
329 |
Fesoterodine + 5-Hydyroxy methyl tolterodine |
Urinary Iincontinence |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.001 0.02 |
0.750 15.0 |
330 |
Fexofenadine |
Antihistamine |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
8.00 |
1000 |
331 |
Fexofenadine |
Antihistaminer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
4.00 |
2000 |
332 |
Fexofenadine |
Antihistamine |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
4.00 |
2000 |
333 |
Fexofenadine + Pseudoephedrine |
Antihistamine |
Human Blood |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
1500 |
334 |
Fexofenadine + Pseudoephedrine (Sensitive) |
Antihistamine |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
Premier XE |
1.00 2.00 |
500 1000 |
335 |
Flibanserin |
HypoactiveSsexual Desire Disorder (HSDD) |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
4.00 |
1400 |
336 |
Fingolimod |
Multiple sclerosis |
Human Blood |
K3EDTA |
LC/MS/MS |
API 5500 |
0.010 |
5.00 |
337 |
Flecainide |
Anti–arrhythmic |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
2.00 |
800 |
338 |
Fluconazole |
Antifungal |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
50 |
10000 |
339 |
Fluconazole |
Antifungal |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
20.0 |
8000 |
340 |
Flucytosine |
Antimycotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
30.0 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
341 |
Flucytosine |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
30.0 |
342 |
Fludrocortisone |
Glucocorticoid |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 5500 |
0.025 |
2.50 |
343 |
Fluoxetine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
100 |
344 |
Fluoxetine + Norfluoxetine |
Antidepressant |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
2.00 |
400 |
345 |
Fluphenazine |
Antipsychotic |
Human Plasma |
Sodium Heparin |
LC/MS/MS |
LCMS-8040 |
0.020 |
5.00 |
346 |
Free Dabigatran |
Thrombin Inhibitor |
Human Plasma |
Sodium citrate |
LC/MS/MS |
LCMS-8050 |
1.000 |
400 |
347 |
Fulvestrant |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.10 |
25.0 |
348 |
Furosemide |
Diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
20.0 |
6000 |
349 |
Gabapentin |
Anticonvulsant |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
40.0 |
10000 |
350 |
Gabapentin |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
40.0 |
6000 |
351 |
Galantamine |
Alzheimer's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.25 |
150 |
352 |
Gefitinib |
Anticancer |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.50 |
250 |
353 |
Gefitinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
1.50/td>
| 450 |
354 |
Glibenclamide (Glyburide) |
Antidiabetic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
1.00 |
500 |
355 |
Glibenclamide (Glyburide) |
Antidiabetic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 2000 |
2.00 |
800 |
356 |
Glibenclamide + Metformin |
Antidiabetic |
Human Blood |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
2.00 10.0 |
600 3000 |
357 |
Gliclazide |
Antidiabetic |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
50.0 |
5000 |
358 |
Gliclazide |
Antidiabetic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
50.0 |
12000 |
359 |
Glimepiride |
Antidiabetic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
1.00 |
500 |
360 |
Glimpiride |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.00 |
500 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
361 |
Glimepiride |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
800 |
362 |
Glipizide |
Antidiabetic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
5.00 |
2000 |
363 |
Glycopyrronium |
Anticholinergic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 pg/mL |
500 pg/mL |
364 |
Griseofulvin |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
4000 |
365 |
Granisetron |
Anti–emetic |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
0.15 |
15 |
366 |
Granisetron |
Anti–emetic |
Human Plasma |
Sodium citrate |
LC/MS/MS |
API 3000 |
0.10 |
30.0 |
367 |
Granisetron |
Anti–emetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.15 |
150 |
368 |
Griseofulvin |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
5000 |
369 |
Guaifenesin |
Expectorant |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
43.77 |
5606 |
370 |
Guaifenesin |
Expectorant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
15.0 |
6000 |
371 |
Guaifenesin |
Expectorant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
12.5 |
5000 |
372 |
Guanfacine |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 5500 |
0.025 |
10.0 |
373 |
Guanfacine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.05 |
20.0 |
374 |
Hydralazine |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 |
200 |
375 |
Hydrochlorothiazide |
Diuretic |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
2.00 |
500 |
376 |
Hydrochlorothiazide |
Diuretic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
1.00 |
500 |
377 |
Hydrochlorothiazide |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
1.00 |
250 |
378 |
Hydrochlorothiazide + Irbesartan |
Antihypertensive Diuretic |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 3000 |
1.00 30.0 |
250 7500 |
379 |
Hydrochlorothiazine + Telmisartan |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
1.50 5.00 |
300 1000 |
380 |
Hydrochlorothiazide + Metoprolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 0.15 |
500 75.0 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
381 |
Hydrocortisone |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
1000 |
382 |
Hydrocortisone (Free ) |
Glucocorticoid |
Human Plasma | 669
CPDA, EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 |
80.0 |
383 |
Hydrocortisone (Free ) |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 |
50.0 |
384 |
Hydrocortisone (Total) |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 |
500 |
385 |
Hydroxycarbamide (Hydroxyurea) |
Anticancer |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
100 |
30000 |
386 |
Hydroxychloroquine |
Antimalarial |
Human Plasma |
Sodium citrate |
LC/MS/MS |
API 2000 |
2.00 |
600 |
387 |
Ibrutinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
100 |
388 |
Ibuprofen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
500 |
100000 |
389 |
Ibuprofen |
NSAID |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
150 |
30000 |
390 |
Ibuprofen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
250 |
100000 |
391 |
Idelasisib |
Chronic lymphocytic leukemia |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
10.0 |
4000 |
392 |
Imatinib |
Anticancer |
Human Plasma |
EDTA |
LC/MS/MS |
API2000 |
25.0 |
8000 |
393 |
Imatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
25.00 |
6000 |
394 |
Imatinib + N-Desmethyl Imatinib |
Anticancer |
Human Plasma |
EDTA |
LC/MS/MS |
API 3200 |
20.0 2.00 |
10000 1000 |
395 |
Indapamide |
Antihypertensive |
Human Blood |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
100 |
396 |
Indomethacin |
Nonsteroidal anti-inflammatory |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
25.0 |
5000 |
397 |
Indoramin |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.04 |
80 |
398 |
Ipratropium |
Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.60 pg/mL |
180 pg/mL |
399 |
Irbesartan + Hydrochlorothiazide |
Antihypertensive Diuretic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
10.0 1.00 |
5000 500 |
400 |
Irbesartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
30.0 |
7500 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
401 |
Iron |
Iron Defficiency Anaemia |
Human Plasma |
K3EDTA |
ICP OES |
Optima 8000 |
400 |
20000 |
402 |
Isosorbide 5-mononitrate |
Angina Pectoris, Congestive Heart Failure |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
10.0 |
1000 |
403 |
Isotretinoin |
Anti-acne |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
2000 |
404 |
Isotretinoin |
Anti-acne |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
1000 |
405 |
Itraconazole |
Antifungal |
Human Plasma |
CPDA, K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
600 |
406 |
Itraconazole |
Antifungal |
Human Plasma |
Sodium citrate |
LC/MS/MS |
LCMS-8050 |
1.00 |
1000 |
407 |
Itraconazole + Hydroxy Itraconazole |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
600 |
408 |
Ivabradine |
Heart rate lowering agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.25 |
100 |
409 |
Ivabradine + N-desmethyi ivabradine |
Heart rate lowering agent |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 0.050 |
100 25.0 |
410 |
Ivacaftor |
Cystic fibrosis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
2.00 |
2000 |
411 |
Ivermectin |
anthelmintics |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
80.0 |
412 |
Ketoprofen |
Anti-Inflammatory, Analgesic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
20.0 |
10000 |
413 |
Ketorolac |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
10.0 |
2000 |
414 |
Ketotifen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.002 |
1.00 |
415 |
Lacosamide |
Antiepileptic |
Human Blood |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
50.0 |
10000 |
416 |
Labetalol |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
1.0 |
500 |
417 |
Lacosamide |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
50.0 |
20000 |
418 |
Lamivudine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
60.0 |
6000 |
419 |
Lamivudine |
Antiviral |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
20.0 |
6000 |
420 |
Lamivudine + Tenofovir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
20.0 5.00 |
4000 1000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
421 |
Lamivudine + Zidovudine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
40.0 60.0 |
4000 6000 |
422 |
Lamivudine + Abacavir |
Antiviral |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
55.0 30.0 |
11000 6000 |
423 |
Lamivudine + Nevirapine + Zidovudine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
50.0 |
6000 |
424 |
Lamuvudine + Nevirapine + Zidovudine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
40.0 50.0 60.0 |
4000 5000 6000 |
425 |
Lamotrigine |
Anticonvulsant, Anti–epileptic |
Human Plasma |
CPDA, K3EDTA |
LC/MS/MS |
Premier XE |
40.0 |
10000 |
426 |
Lamotrigine |
Anticonvulsant, Anti–epileptic |
Human Plasma |
Sodium citrate |
LC/MS/MS |
API 4000 |
5.00 |
4000 |
427 |
Lamotrigine |
Anticonvulsant, Anti–epileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
20.0 |
10000 |
428 |
Lansoprazole |
Proton pump inhibitor |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
5.00 |
2000 |
429 |
Lansoprazole/td>
| Proton pump inhibitor |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
2.00 |
2000 |
430 |
Lansoprazole |
Proton-pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
2500 |
431 |
Lansoprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.50 |
2500 |
432 |
Lansoprazole |
Proton pump inhibito |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
2.50 |
2500 |
433 |
Lapatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
5000 |
434 |
Lapatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
3.00 |
1500 |
435 |
Ledipasvir + Sofosbuvir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
2.00 3.00 |
1000 1500 |
436 |
Lenalidomide |
Anticancer (Multiple myeloma) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
2.00 |
1000 |
437 |
Lenalidomide |
Anticancer (Multiple myeloma) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.50 |
100 |
438 |
Lenvatinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.40 |
400 |
439 |
Letrozole |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
100 |
440 |
Letrozole |
Breast Cancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
1.00 |
400 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
441 |
Leuprolide (Leuprorelin) |
Prostate cancer, Breast cancer |
Human Serum |
NA |
LC/MS/MS |
API 5500 |
40.0 60.0 |
4000 6000 |
442 |
Leuprolide (Leuprorelin) |
Prostate cancer, Breast cancer |
Human Serum |
NA |
LC/MS/MS |
LCMS-8050 |
0.50 |
200 |
443 |
Leuprolide (Leuprorelin) |
Prostate cancer, Breast cance |
Human Serum |
NA |
LC/MS/MS |
LCMS-8050 |
0.020 |
120 |
444 |
Levetiracetam |
Anti–epileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
300 |
60000 |
445 |
Levetiracetam |
Anti–epileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
300 |
60000 |
446 |
Levocarnitine |
Primary systemic carnitine deficiency |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
100 |
20000 |
447 |
Levocetirizine |
Non-sedative antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
10.0 |
600 |
448 |
Levofloxacin |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
100 |
16000 |
449 |
Levofloxacin |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
80.0 |
20000 |
450 |
Levofloxacin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
80.0 |
20000 |
451 |
Levomepromazine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.025 |
15.0 |
452 |
Levosalbutamol |
Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.005 |
1.00 |
453 |
Levothyroxine |
Thyroid Hormone Defficiency |
Human Serum |
NA |
LC/MS/MS |
Premier XE |
10.0 |
1000 |
454 |
Levothyroxine + Liothyronine |
Thyroid Hormone Defficiency |
Human Serum |
NA |
LC/MS/MS |
LCMS-8050 |
20.0 0.30 |
1000 15.0 |
455 |
Levothyroxine + Liothyronine |
Thyroid Hormone Defficiency |
Human Serum |
NA |
LC/MS/MS |
LCMS-8050 |
20.0 0.30 |
800 12.0 |
456 |
Lidocaine |
Local Anesthetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.200 |
200 |
457 |
Lidocaine + Prilocaine |
Local Anesthetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.60 0.40 |
300 200 |
458 |
Linagliptin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.035 |
14.0 |
459 |
Linezolid |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
100 |
24000 |
460 |
Lisinopril |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
1.00 |
200 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
461 |
Lisinopril |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
60 |
462 |
Lisinopril |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
200 |
463 |
Lisinopril |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
700 |
464 |
Lithium |
Antidepressant |
Human Plasma |
K3EDTA |
ICP OES |
Optima 8000 |
50.0 |
5000 |
465 |
Loperamide |
Antidiarrheal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.010 |
4.00 |
466 |
Loperamide |
Antidiarrheal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.005 |
6.00 |
467 |
Loperamide + N-Desmethyl Loperamide |
Antidiarrheal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.010 0.010 |
4.00 4.00 |
468 |
Lopinavir + Ritonavir |
Antiretroviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
30.0 3.00 |
15000 1500 |
469 |
Loratadine + Desloratadine |
Antihistamine |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
0.20 |
50.0 |
470 |
Loratadine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.075 |
25.0 |
471 |
Lorcaserin |
Weight Loss |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.40 |
200 |
472 |
Losartan |
Angiotensin II Receptor Antagonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.00 |
500 |
473 |
Lumefantrine |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
50.0 |
20000 |
474 |
Lumafantrine |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
50.0 |
30000 |
475 |
Lurasidone |
Antipsychotic |
Human Serum |
NA |
LC/MS/MS |
API4000 |
0.25 |
150 |
476 |
Lurasidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.25 |
150 |
477 |
Magnesium |
Hypomagnesaemia |
Human Serum |
NA |
ICP OES |
Optima 8000 |
2000 |
150000 |
478 |
Magnesium |
Hypomagnesaemia |
Human Urine |
NA |
ICP OES |
Optima 8000 |
2000 |
350000 |
479 |
Macitentan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
500 |
480 |
Maraviroc |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
500 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
481 |
Mebendazole |
Anthelmintic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.020 |
30.0 |
482 |
Meclizine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.50 |
300 |
483 |
Mefenamic Acid (Sensitive) |
Non-steroidal Anti- inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
40.5 |
12000 |
484 |
Mefenamic Acid (Sensitive) |
Non-steroidal Anti- inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
20.0 |
11000 |
485 |
Mefenamic acid |
Non steroial anti inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
30.0 |
12000 |
486 |
Meloxicam |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
20.0 |
8000 |
487 |
Memantine |
Anti-Alzheimer's |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
0.50 |
100 |
488 |
Mexiletine |
Antiarrhythmic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
2.00 |
1000 |
489 |
Mercaptopurine |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
80.0 |
490 |
Mesalamine |
Anti-inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
2000 |
491 |
Mesalamine |
Anti-inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
2000 |
492 |
Mesalamine |
Anti-inflammatory |
Human Plasma |
K3EDTA |
LC/MS/MS |
Waters QPXE |
25.0 |
12500 |
493 |
Metaxalone |
Muscle Relaxant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
5000 |
494 |
Metformin |
Antidiabetic |
Human Plasma |
EDTA |
HPLC |
HPLC-UV |
40.0 |
7500 |
495 |
Metformin |
Antidiabetic |
Human Serum |
NA |
LC/MS/MS |
API 2000 |
40.0 |
7500 |
496 |
Metformin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
20.0 |
7500 |
497 |
Metformin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
4.00 |
800 |
498 |
Metformin + Sitagliptin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 2.00 |
4000 800 |
499 |
Metformin + Vildagliptin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 2.00 |
4000 800 |
500 |
Metformin + Vildagliptin |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 2.00 |
4000 1600 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
501 |
Mebendazole |
Urinary Tract Infection |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
0.050 |
20.0 |
502 |
Methimazole |
Antithyroid |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 |
500 |
503 |
Methocarbamol |
Musculoskeletal relaxant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premiere XE |
100 |
30000 |
504 |
Methotrexate |
Anticancer |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
1.00 |
250 |
505 |
Methotrexate |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
600 |
506 |
Methoxsalen |
Dermatological |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
1.00 |
200 |
507 |
Methoxsalen (Sensitive) |
Dermatological |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.10 |
100 |
508 |
Methyl Ergonovine |
Postpartum Hemorrhage |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.040 |
10.0 |
509 |
Methylphenidate |
CNS Stimulant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
100 |
510 |
Methyl Prednisolone |
corticosteroid hormone |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
40 |
511 |
Methyl Prednisolone |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.20 |
100 |
512 |
Methyl Prednisolone |
Glucocorticoid |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
5.00 |
4000 |
513 |
Metolazone |
Diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.15 |
150 |
514 |
Metolazone |
Diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.20 |
250 |
515 |
Metopimazine + Metopimazine Acid |
Antiemetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 0.40 |
100 200 |
516 |
Metoprolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
0.30 |
300 |
517 |
Metoprolol |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.30 |
300 |
518 |
Metoprolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.30 |
300 |
519 |
Metronidazole |
Antiamoebic |
Human Plasma |
CPDA, EDTA |
HPLC |
HPLC-UV |
100 |
40000 |
520 |
Metronidazole |
Antiamoebic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
100 |
40000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
521 |
Metronidazole |
Antiamoebic |
Human Stool |
NA |
LC/MS/MS |
API 4000 |
0.50 |
250 |
522 |
Midazolam + 1-Hydroxy Midazolam |
Anxiolytic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.30 0.10 |
60.0 20.0 |
523 |
Minocycline |
Antibiotic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
10.0 |
3000 |
524 |
Minocycline |
Antibiotic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
10.0 |
3000 |
525 |
Mirabegron |
Urinary incontinence |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 5500 |
0.100 |
80.0 |
526 |
Mometasone |
Corticosteroid, Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.20 pg/mL |
30.0 pg/mL |
527 |
Mono Methyl Fumarate |
Multiple Sclerosis |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
10.0 |
5000 |
528 |
Montalukast+ Fexofenadin |
leukotriene receptor antagonist Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
1000 |
529 |
Montelukast |
Lukotriene receptor antagonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
1000 |
530 |
Montelukast |
eukotriene receptor antagonist |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
5.00 |
1000 |
531 |
Montelukast |
Lukotriene receptor antagonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
400 |
532 |
Moxifloxacin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
40.0 |
5000 |
533 |
Moxifloxacin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
40.0 |
10000 |
534 |
Moxifloxacin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
30.0 |
15000 |
535 |
Mycophenolic acid |
Immunosuppressant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
300 |
50000 |
536 |
Mycophenolic acid |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
40.5 |
20000 |
537 |
Mycophenolate Acid |
Immunosuppressant |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
40.0 |
20000 |
538 |
Mycophenolic Acid |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
200 |
50000 |
539 |
Mycophenolic Acid |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.0 |
20000 |
540 |
Mycophenolic Acid |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
60.0 |
30000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
541 |
Mycophenolic acid |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
100 |
50000 |
542 |
Mycophnolic Acid |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
60.0 |
30000 |
543 |
Mycophenolate Mofetil |
Immunosuppressant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
20.0 |
800 |
544 |
Mycophenolate Mofetil |
Immunosuppressant |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.10 |
16.0 |
545 |
Mycophenolate Mofetil |
Immunosuppressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.01 |
10.0 |
546 |
Nadolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
1.00 |
600 |
547 |
Nafithromycin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
10.0 |
5000 |
548 |
Naltrexone + 6ß Naltrexone |
Opioid antagonist |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 0.50 |
35.0 175 |
549 |
Naproxen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
10000 |
550 |
Naproxen |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
500 |
150000 |
551 |
Naproxen |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
400 |
200000 |
552 |
Naratriptan |
Anti-migraine |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.10 |
20.0 |
553 |
Naratriptan |
Anti-migraine |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.050 |
25.0 |
554 |
Nateglinide |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
50.0 |
12000 |
555 |
Nebivolol |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.05 |
5.00 |
556 |
Nebivolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.04 |
15.0 |
557 |
Nebivolol |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.030 |
40.0 |
558 |
Nefopam |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
200 |
559 |
Nefopam |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.50 |
200 |
560 |
Nevirapine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
50.00 |
5000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
561 |
Nicardipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 |
130 |
562 |
Nifedipine |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.40 |
200 |
563 |
Nifedipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.10 |
50.0 |
564 |
Nifedipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.25 |
100 |
565 |
Nifedipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
250 |
566 |
Nilutamide |
Antiandrogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
40.0 |
8000 |
567 |
Nilotinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
6.00 |
3000 |
568 |
Nilotinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
12.0 |
6000 |
569 |
Nimodipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 |
50.0 |
570 |
Nintedanib |
Idiopathic pulmonary fibrosis (IPF) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
30.0 |
571 |
Nitisinone |
Hereditary tyrosinemia type 1 (HT-1) |
Human Plasma |
NA |
LC/MS/MS |
API 4000 |
10.0 |
10000 |
572 |
Nitrofurantoin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
1500 |
573 |
Nitrofurantoin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
600 |
574 |
Nitrofurantoin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.75 |
1500 |
575 |
Nizatidine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
20.0 |
5000 |
576 |
Norethisterone (Norethindrone) |
Progestogen |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.50 |
100 |
577 |
Norfloxacin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
25.0 |
8000 |
578 |
Nortriptyline |
Antidepressant |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
0.50 |
220 |
579 |
Nortriptyline |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 |
50.0 |
580 |
Nortryptiline + E-10-Hydroxy Nortryptiline |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 0.20 |
50.0 100 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
581 |
Octreotide |
Growth hormone producing tumors |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8060 |
0.050 |
15.0 |
582 |
Ofloxacin |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
25.0 |
8000 |
583 |
Olanzapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.50 |
50.0 |
584 |
Olaparib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
50.0 |
20000 |
585 |
Olmesartan |
Angiotensin II receptor antagonis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
3000 |
586 |
Olmesartan + Hydrochlorothiazide |
Angiotensin II receptor antagonist diuretic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 1.00 |
3000 300 |
587 |
Olanzepine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
30.0 |
588 |
Olanzapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
0.30 |
120 |
589 |
Olsalazine |
Ulcerative colitis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
20.0 |
2000 |
590 |
Omeprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 |
2000 |
591 |
Omeprazole |
Proton Pump Inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
2.00 |
2000 |
592 |
Ondansetron |
Anti–emetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.20 |
80.0 |
593 |
Orphenadrine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
4.00 |
800 |
594 |
Oseltamivir + Oseltamivir Carobxylate |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 2.00 |
250 1000 |
595 |
Oseltamivir + Oseltamivir Carboxylate |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.50 2.00 |
200 800 |
596 |
Osimertinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.25 |
200 |
597 |
Ospemifene |
Dyspareunia |
Human Plasma |
NA |
LC/MS/MS |
LCMS-8040 |
5.00 |
2000 |
598 |
Oxaprozin Total |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
500 |
160000 |
599 |
Oxcarbazepine + 10, 11-Dihydro-10-hydroxy-Carbamazepine |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
20.0 75.0 |
4000 15000 |
600 |
Oxybutynin + Metabolite- N-Desethyl Oxybutynin |
Anticholinergic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.05 0.50 |
10.0 100 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
601 |
Oxybutynin + N-Desethyl Oxybutynin |
Anticholinergic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.050 0.20 |
50.0 200 |
602 |
Paclitaxel (Total) |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
5.00 |
15000 |
603 |
Paclitaxel (Total) |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
80.0 |
40000 |
604 |
Palbociclib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
200 |
605 |
Paliperidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
150 |
606 |
Paliperidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 |
50.0 |
607 |
Paliperidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.050 |
50.0 |
608 |
Paliperidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
250 |
609 |
Paliperidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
120 |
610 |
Pantoprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
15.0 |
5000 |
611 |
Pantoprazole |
Proton Pump Inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
6000 |
612 |
Pantoprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 |
8000 |
613 |
Paroxetine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.40 |
200 |
614 |
Paroxetine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
0.40 |
60.0 |
615 |
Paroxetine |
Antidepressant |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.040 |
24.0 |
616 |
Pazopanib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
100 |
40000 |
617 |
Pazopanib |
Anticancer |
Human Plasma |
NA |
LC/MS/MS |
API 4000 |
100 |
80000 |
618 |
Pazopanib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
300 |
150000 |
619 |
Pazopanib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2300 |
150000 |
620 |
Pemetrexed |
Lung Cancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
500 |
200000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
621 |
Perampanel |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
1.00 |
1000 |
622 |
Phenobarbital |
Antiepileptic |
Human Plasma |
K2EDTA |
LC/MS/MS |
Premier XE |
10.0 |
4000 |
623 |
Phenytoin |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
5000 |
624 |
Phenytoin |
Phenytoin |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
60.0 |
12000 |
625 |
Phloroglucinol |
Antispasmodic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
10.0 |
2500 |
626 |
Phloroglucinol |
Antispasmodic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
10.0 |
2500 |
627 |
Pimozide |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.02 |
5.00 |
628 |
Pindolol |
Beta Blocker |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
1.00 |
400 |
629 |
Pioglitazone + Hydroxy Pioglitazone M IV |
Antihyperglycemic, antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
10.0 5.00 |
3000 1500 |
630 |
Piperaquine |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
300 |
631 |
Piribedil |
Antiparkinsonian |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
200 |
632 |
Pirfenidone |
Idiopathic pulmonary fibrosis (IPF) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
50.0 |
25000 |
633 |
Pirfenidone |
Idiopathic pulmonary fibrosis (IPF) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
50.0 |
30000 |
634 |
Pirfenidone |
Idiopathic pulmonary fibrosis (IPF) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
10.0 |
10000 |
635 |
Piroxicam |
NSAID |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
10.0 |
10000 |
636 |
Pomalidomide |
Anticancer (Multiple Myeloma) |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 |
150 |
637 |
Posaconazole |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
API3000 |
2.00 |
2000 |
638 |
Pramipexole |
Antiparkinsonian |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.02 |
4.00 |
639 |
Pravastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
0.40 |
200 |
640 |
Pravastatin |
Antihyperlipidemic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.30 |
200 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
641 |
Praziquantel |
Anthelmintic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
10.0 |
4000 |
642 |
Prazosin |
Antihypertensive |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 4000 |
0.20 |
60.0 |
643 |
Pregabalin |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
30.0 |
15000 |
644 |
Pregabalin |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
15.0 |
4000 |
645 |
Pregabalin+ Gabapentin+ Carbamazepine+ Levetiracetam |
Antiepileptic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
30.0 100 10.0 60.0 |
6000 20000 2000 120000 |
646 |
Primaquine |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
0.50 |
200 |
647 |
Primidone |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
50.00 |
40000 |
648 |
Primidone |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
10.0 |
3000 |
649 |
Propafenone+ 5- Hydroxy Propafenone |
Antiarrhythmic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 0.20 |
400 400 |
650 |
Pottasium |
Hypokalaemia |
Human Plasma |
NA |
ICP OES |
Optima 8000 |
20000 |
3000000 |
651 |
Prasugrel Metabolite R95913 |
Platelet Inhibitor (Prasugrel) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
100 |
652 |
Prochlorperazine |
Tranquilliser |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.002 |
0.600 |
653 |
Prochlorperazine |
Tranquilliser |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.01 |
3.00 |
654 |
Procyclidine |
Anticholinergic, Antiparkinsonian |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
1.00 |
300 |
655 |
Proguanil |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
5.00 |
1000 |
656 |
Promethazine |
Antihistaminic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API2000 |
0.20 |
60.0 |
657 |
Propofol |
Sedative-hypnotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
5.00 |
5000 |
658 |
Propafenone + 5-Hydroxy metabolite |
Anti-arrhythmic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
5.00 2.50 |
1000 500 |
659 |
Propranolol + 4-Hydroxy Propranolol(Free) |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.10 0.30 |
100 30.0 |
660 |
Pyrazinamide |
Antitubercular |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
200 |
60000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
661 |
Pyridostigmine |
Anticholinesterase |
Human Plasma |
K3EDTA |
LC/MS/MS |
Anticholinesterase |
0.50 |
150 |
662 |
Pyridostigmine |
Anticholinesterase |
Human Plasma |
K2EDTA |
LC/MS/MS |
API 5500 |
0.50 |
150 |
663 |
Pyrimethamine |
Antibacterial, Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
2.00 |
1000 |
664 |
Quetiapine |
Antipsychotic |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
2.00 |
2000 |
665 |
Quetiapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 |
200 |
666 |
Quetiapine |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 |
600 |
667 |
Quinine |
Antimalarial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
40.0 |
8000 |
668 |
Quinidine |
Antianginal |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
4.0 |
4000 |
669 |
Rabeprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
3.00 |
2000 |
670 |
Rabeprazole |
Proton pump inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
3.00 |
1000 |
671 |
Rabeprazole |
Proton pump inhibito |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
4.00 |
2000 |
672 |
Raltegravir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
20.0 |
3000 |
673 |
Raltegravir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
20.0 |
10000 |
674 |
Raltegravir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
10000 |
675 |
Ramipril |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
0.20 |
100 |
676 |
Ramipril+ Ramiprilat |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 |
100 |
677 |
Ranitidine |
Antihistamine (H2 Antagonist) |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
5.00 |
1000 |
678 |
Ranitidine |
Antihistamine |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
10.0 |
3000 |
679 |
Ranolazine |
Antianginal |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
4.00 |
8000 |
680 |
Ranolazine |
Antianginal |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premiere XE |
10.0 |
6000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
681 |
Rasagiline |
Parkinsons disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
Waters |
0.02 |
10.0 |
682 |
Repaglinide |
Antidiabetic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
0.50 |
200 |
683 |
Repaglinide + 3-Hydroxy Repaglinide |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 0.050 |
10.0 10.0 |
684 |
Rifampicin |
Antitubercular |
Human Plasma |
EDTA |
LC/MS/MS |
LCMS-8060 |
0.50 |
200 |
685 |
Rifampicin + 25-Desacetyl Rifampicin |
Antitubercular |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
100 10.0 |
20000 2000 |
686 |
Rifaximin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.025 |
10.0 |
687 |
Rifaximin |
Antibiotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.009 |
12.0 |
688 |
Rilpivirin |
Non-nucleoside Reverse Transcriptase Inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
2.00 |
500 |
689 |
Riluzole |
Amyotrophic lateral sclerosis |
Human Plasma |
K3EDTA |
LC/MS/MS |
Amyotrophic lateral sclerosis |
1.00 |
500 |
690 |
Risperidone + 9-Hydroxy Risperidone |
Antipsychotic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 0.20 |
100 100 |
691 |
Ritonavir |
Antiretroviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
2.50 |
1500 |
692 |
Rivoroxaban |
Oral Anticoagulant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
1.00 |
800 |
693 |
Rivaroxaban |
Oral Anticoagulant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
500 |
694 |
Rivaroxaban |
Oral Anticoagulant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
800 |
695 |
Rivastigmine |
Alzheimer's&Parkinson's Disease |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
0.10 |
50.0 |
696 |
Rizatriptan |
Anti-migraine |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.10 |
100 |
697 |
Rizatriptan |
Anti-Migraine |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
0.10 |
60.0 |
698 |
Roflumilast |
Severe COPD associated with chronic bronchitis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.100 |
20.0 |
699 |
Roflumilast + Roflumilast N-Oxide |
Severe COPD associated with chronic bronchitis |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 0.25 |
40.0 50.0 |
700 |
Ropinirole |
Antiparkinsonian |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.02 |
4.00 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
701 |
Ropinirole |
Antiparkinsonian |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.02 |
4.00 |
702 |
Rosiglitazone + Metformin |
Antidiabetic |
Human Plasma |
EDTA |
LC/MS/MS |
API 2000 |
6.00 40.0 |
1100 7600 |
703 |
Rosiglitazone + N-Desmethyl Rosiglitazone |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 2.50 |
1000 500 |
704 |
Rosuvastatin |
Antihyperlipidemic |
Human Plasma |
EDTA |
LC/MS/MS |
Premier XE |
0.60 |
100 |
705 |
Rosuvastatin |
Lowering Cholestero |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
150 |
706 |
Rosuvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
200 |
707 |
Rosuvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.10 |
50.0 |
708 |
Rotigotine |
Antiparkinsonian |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.002 |
1.20 |
709 |
Rufinamide |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
30.0 |
9000 |
710 |
Salmeterol |
Asthma |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.001 |
0.50 |
711 |
Sacubitril + Valsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
15.0 25.0 |
6000 10000 |
712 |
Sacubitril + Sacubitrilat + Valsartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
15.0 50.0 25.0 |
6000 20000 10000 |
713 |
Scopolamine |
Anticholinergic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.005 |
0.50 |
714 |
Secnidazole |
Antiamoebic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
200 |
80000 |
715 |
Secnidazole |
Antiamoebic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
200 |
80000 |
716 |
Sertraline |
Antidepressant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 2000 |
1.50 |
300 |
717 |
Sertraline |
Antidepressant |
Human Plasma |
EDTA |
LC/MS/MS |
LCMS-8040 |
0.20 |
80.0 |
718 |
Sildenafil |
Antihypertensive, Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
8.00 |
1040 |
719 |
Sildenafil + Metabolite |
Antihypertensive, Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
2.00 |
1000 |
720 |
Sildenafil + Piperazine N-desmethyl Sildenafil |
Antihypertensive, Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
5.00 1.00 |
2000 400 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
721 |
Sildenafil + N-desmethyl sildenafil |
Antihypertensive, Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
1.00 0.20 |
500 100 |
722 |
Sildenafil + N-desmethyl Sildenafil |
Antihypertensive, Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
1.00 0.20 |
500 100 |
723 |
Silodosin + Silodsoin Glucuronide |
Benign prostatic hyperplasia |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.50 0.40 |
300 240 |
724 |
Siimvastatin |
Antihyperlipidemic |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
0.040 |
20.0 |
725 |
Simvastatin |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.040 |
32.0 |
726 |
Simvastatin Acid |
Antihyperlipidemic |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
0.02 |
7.50 |
727 |
Simvastatin Acid |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.015 |
12.0 |
728 |
Simvastatin + β - hydroxy Acid |
Antihyperlipidemic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.50 |
100 |
729 |
Simvastatin + β - hydroxy Acid |
Antihyperlipidemic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.25 |
32.0 |
730 |
Simvastatin + Simvastatin acid |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.200 0.200 |
100 100 |
731 |
Simvastatin + Simvastatin Acid |
Antihyperlipidemic |
Human Plasma |
Na Heparin |
LC/MS/MS |
API 4000 |
0.50 0.50 |
200 200 |
732 |
Simvastatin + Simvastatin Hydroxy Acid |
Antihyperlipidemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 5500 |
0.20 0.10 |
200 100 |
733 |
Sirolimus |
Immunosuppressant |
Human Blood |
EDTA |
LC/MS/MS |
API 4000 |
0.40 |
40.0 |
734 |
Sirolimus (Sensitive) |
Immunosuppressant |
Human blood |
K3EDTA |
LC/MS/MS |
Premier XE |
0.10 |
50.0 |
735 |
Sirolimus |
immunosuppressants |
Human blood |
EDTA |
LC/MS/MS |
LCMS-8040 |
0.10 |
40.0 |
736 |
Sitagliptin |
Antihyperglycemic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
800 |
737 |
Sodium Phenyl Butyrate + Metabolite Phenyl acetate+ Metabolite Phenylacetylglutamine |
For Urea cycle disorders |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5 µg/mL 1 µg/mL 2 µg/mL |
750 µg/mL 750µg/mL 300 µg/mL |
738 |
Sofosbuvir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
5.00 |
2000 |
739 |
Sofosbuvir + Sofosbuvir GS331007 |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LC 8040 |
5.00 10.0 |
1500 3000 |
740 |
Solifenacin |
Urinary antispasmodic |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
125 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
741 |
Solifenacin (Sensitive) |
Antimuscarinic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.20 |
130 |
742 |
Sorafenib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
50.0 |
10000 |
743 |
Sorafenib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
20.0 |
8000 |
744 |
Sotalol |
Antiarrhythmic |
Human Plasma |
Na Heparin |
LC/MS/MS |
LCMS-8050 |
10.0 |
3000 |
745 |
Spironolactone |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
250 |
746 |
Spironolactone |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.50 |
250 |
747 |
Sulfadiazine |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
250 |
40000 |
748 |
Sulphamethoxazole + Trimethoprim |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
0.50 0.025 |
100 5.00 |
749 |
Sulfamethoxazole + Trimethoprim |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 / LCMS- 8050 |
150 5.00 |
30000 1000 |
750 |
Sumatripatan |
Anti-migraine |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 |
100 |
751 |
Sunitinib |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.25 |
100 |
752 |
Sulfadoxine |
Antibacterial |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
1000 |
400000 |
753 |
Tacrolimus |
Immunosuppressant |
Human Blood |
EDTA |
LC/MS/MS |
Premier XE |
0.50 |
100 |
754 |
Tacrolimus |
Immunosuppressant |
Human blood |
EDTA |
LC/MS/MS |
Premier XE |
0.25 |
75.0 |
755 |
Tacrolimus |
immunosuppressants |
Human blood |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
75.0 |
756 |
Tadalafil |
Antihypertensive, Erectile dysfunction |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
2.00 |
800 |
757 |
Tamsulosin |
Prostatic hyperplasia |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.050 |
30.0 |
758 |
Tamsulosin |
α1a-selective alpha blocker |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.20 |
100 |
759 |
Tapentadol |
Analgesic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.10 |
1200 |
760 |
Telmisartan |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
3.00 |
1200 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
761 |
Telmisartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
1000 |
762 |
Telmisartan |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8040 |
2.00 |
500 |
763 |
Telmisartan + Amlodipine |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
2.50 0.075 |
500 15.0 |
764 |
Temozolamide |
Anticancer |
Human Plasma |
Na Heparin |
LC/MS/MS |
Premier XE |
100 |
20000 |
765 |
Temozolomide |
Anticancer |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
100 |
20000 |
766 |
Tenofovir |
Antiviral |
Human Plasma |
NA |
LC/MS/MS |
API 2000 |
5.00 |
1000 |
767 |
Tenofovir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 |
1000 |
768 |
Tenofovir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.40 |
50.0 |
769 |
Tenofovir + Emtricitabine + Lamivudine |
Antibacterial |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
4.00 15.0 20.0 |
800 3000 4000 |
770 |
Tenofovir |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
5.00 |
1000 |
771 |
Tenofovir+ Emtricitabine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
8.00 30.0 |
1600 6000 |
772 |
Tenofovir + Emtricitabine + Rilpivirine |
Antiritroviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
4.00 20.0 1.00 |
800 4000 200 |
773 |
Tenofovir + Emtricitabine + Nevirapine |
Antiritroviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
4.00 20.0 20.0 |
800 4000 4000 |
774 |
Tenofovir Alafenamide |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
2.00 |
1000 |
775 |
Tenofovir Alafenamide + Lamivudine |
Antiviral |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
2.00 20.0 |
500 5000 |
776 |
Terbinafine |
Antifungal |
Human Plasma |
EDTA |
HPLC |
HPLC-UV |
25.0 |
5000 |
777 |
Terbinafine |
Antifungal |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
10.0 |
3000 |
778 |
Teriflunomide |
Multiple sclerosis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
10.0 |
4000 |
779 |
Tetrabenazine |
Huntington's disease |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.01 |
2.00 |
780 |
Tetracycline |
Antibiotic |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
20.0 |
8000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
781 |
Thiamine |
Vtamin B1 |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
0.20 |
30.0 |
782 |
Tiagabine |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.50 |
250 |
783 |
TTicagrelor |
Platelet aggregation inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.50 |
1200 |
784 |
Ticagrelor |
Platelet aggregation inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
5.00 |
2500 |
785 |
Ticagrelor+ Desethoxyhydroxy Ticagrelor |
Platelet aggregation inhibitor |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.50 1.00 |
1250 500 |
786 |
Tinidazole |
Antiprotozoal |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
50.0 |
30000 |
787 |
Tizanidine |
Muscle Relexant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.10 |
20.0 |
788 |
Tizanidine |
Muscle Relexant |
Human Plasma |
K3EDTA |
LC/MS/MS |
Premier XE |
0.075 |
20.0 |
789 |
Tizoxanide |
Antiparasitic |
Human Plasma |
K3EDTA |
LC/MS/MS |
LCMS-8050 |
50.0 |
25000 |
790 |
Tofacitinib |
Rheumatoid arthritis |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
0.20 |
100 |
791 |
Tolbutamide |
Antidiabetic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3200 |
500 |
100000 |
792 |
Tolcapone + 3-O-Methyltolcapone |
Reversible inhibitor of catechol- O-methyltransferase (COMT) |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
40.0 2.00 |
8000 400 |
793 |
Tolterodine |
Urinary Iincontinence |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
0.10 |
20.0 |
794 |
Tolterodine + 5-Hydroxy Methyl Tolterodine |
Antimuscarinic |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
0.03 |
10.0 |
795 |
Tolterodine+ 5-Hydroxymethyl Tolterodine |
Antimuscarinic |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 3000 |
0.025 0.025 |
10.0 10.0 |
796 |
Tolterodine + 5-Hydroxymethyl Tolterodine |
Urinary Iincontinence |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
0.10 0.10 |
10.0 10.0 |
797 |
Topiramate |
Anticonvulsant |
Human Plasma |
CPDA, EDTA |
LC/MS/MS |
API 4000 |
18.0 |
5000 |
798 |
Topiramate |
Anticonvulsant |
Human Plasma |
EDTA |
LC/MS/MS |
API 4000 |
5.00 |
5000 |
799 |
Topiramate |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
5.00 |
5000 |
800 |
Topiramate |
Anticonvulsant |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 4000 |
2.00 |
1000 |
-
Validated Method List (Generics)
Sr. No. |
Drug Name |
Theraputic Class |
Matrix |
Anti-Coagulant |
Method |
Equipment |
LLOQ(ng/mL) |
ULOQ(ng/mL) |
801 |
Torsemide |
Antihypertensive |
Human Plasma |
EDTA |
LC/MS/MS |
API 3000 |
20.0 |
6000 |
802 |
Torsemide |
Diuretic, Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
25.0 |
12000 |
803 |
Torsemide |
Antihypertensive |
Human Plasma |
K3EDTA |
LC/MS/MS |
API 2000 |
100 |
25000 |
804 |
Total Iron |
Iron Defficiency Anaemia |
Human Plasma |
NA |
ICP OES |
Optima 8000 |
500 |
60000 |
805 |
Tramadol hydrochloride |
Analgesic |
|